Working… Menu

Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00804921
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : December 9, 2008
Information provided by:
University of Sao Paulo

Brief Summary:

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).

Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Condition or disease Intervention/treatment Phase
Macular Edema Diabetic Retinopathy Macular Degeneration Drug: bevacizumab Procedure: anterior chamber paracentesis Drug: acetazolamide Drug: brimonidine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Official Title: Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results

Primary Outcome Measures :
  1. Intra-ocular pressure variation after intra-vitreous injection of bevacizumab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • macular edema

Exclusion Criteria:

  • pulmonary chronic problems
  • chronic renal failure
  • intraocular inflammation
  • drug or alcohol addiction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00804921

Layout table for location information
School of Medicine - Clinical Hospital
Ribeirao Preto, SP, Brazil, 14049-900
Sponsors and Collaborators
University of Sao Paulo

Layout table for additonal information
Responsible Party: CONEP (Comite Nacional de Etica em Pesquisa) Identifier: NCT00804921     History of Changes
Other Study ID Numbers: IOP After Bevacizumab
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: December 9, 2008
Last Verified: December 2008
Keywords provided by University of Sao Paulo:
intra-ocular pressure
anterior chamber paracentesis
macular edema secondary to diabetic retinopathy or macular degeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Brimonidine Tartrate
Macular Degeneration
Macular Edema
Retinal Diseases
Diabetic Retinopathy
Retinal Degeneration
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action